拜瑞妥的用法和用量

In recent years, new anticoagulant drugs Factor Xa (FXa) inhibitors have received more and more attention among anticoagulant drugs, among which they are representative drugs of FXa inhibitors. Xarelto is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson, with the trade name Xarelto. Xarelto is a highly selective, oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Xarelto does not inhibit thrombin and has no proven effect on platelets. A dose-dependent inhibition of factor xa activity by rivaroxaban has been observed in humans. Today we will learn about the usage and dosage of Xarelto.

  The recommended dose is 10 mg of Xarelto taken orally once daily. If the wound has stopped bleeding, the first medication should be administered between 6 and 10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone. For patients undergoing major hip surgery, a recommended course of treatment is 5 weeks. For patients undergoing major knee surgery, a recommended course of treatment is 2 weeks. If a dose is missed, the patient should take Xarelto immediately and continue taking the dose once daily the next day. Patients can take Xarelto with a meal or alone.

Xarelto comes as red film-coated tablets. Its main active ingredient is: Rivaroxaban, a highly selective oral drug that directly inhibits factor Xa. Clinically indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its main mechanism of action is: inhibitory factor Xa can interrupt the endogenous and exogenous pathways of the coagulation cascade and inhibit the generation of thrombin and thrombosis.

Due to the pharmacodynamic properties of Xarelto, overdose may result in bleeding complications. At the same time, some subgroups of patients are at higher risk of bleeding, such as patients with liver damage and kidney damage. After initiation of treatment, these patients should be monitored closely for signs of bleeding complications.

The above is the usage and dosage, I hope it can help you.